Hledání v detailu akcií
Top akcie
NázevNávštěvy
31 150
1 248
1 134
1 034
932
677
543
518
373
365
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN-0,42
Msft85,8585,861,36
IBM152,46152,49-0,99
DCX70,6170,62-0,38
PFE36,9736,981,43
15.12.2017 16:51:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017 16:50:19
Heron Therapeutics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
15,63 1,46 0,23 272 810
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.12.2017
Popis společnosti
Obecné informace
Název společnostiHeron Therapeutics Inc
TickerHRTX
Kmenové akcie:Ordinary Shares
RICHRTX.O
ISINUS4277461020
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 3.2.2017 139
Akcie v oběhu k 30.9.2017 54 504 647
Počet akcionářů k 31.12.2016 133
MěnaUSD
Kontaktní informace
Ulice4242 Campus Point Ct Ste 200
MěstoSAN DIEGO
PSČ92121-1513
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 503 662 626

Business Summary: Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Heron Therapeutics Inc revenues increased from $0K to $20.7M. Net loss increased 8% to $135M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects "Research and development - Balancing va increase of 26% to $82.1M (expense), Sales and marketing - increase of 65% to $32.4M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 15.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardKevin Tang5030.7.201230.7.2012
President, DirectorRobert Rosen611.5.20131.5.2013
Chief Executive Officer, DirectorBarry Quart6024.4.20171.5.2013
Chief Financial Officer, Senior Vice President - FinanceRobert Hoffman51
Executive Vice President - Drug DevelopmentKimberly Manhard-27.1.201627.1.2016
Senior Vice President, General Counsel, Business Development, Corporate SecretaryDavid Szekeres43
Senior Vice President - Pharmaceutical and Preclinical Research and DevelopmentThomas Ottoboni58
Vice President - Human ResourcesSean Ristine47